Withdrawal That Disrupted Daily Life Was Tied to Relapse in a Small Study | Research

The takeaway

Among 49 dependent cannabis users asked to stop for two weeks, higher day-to-day interference from withdrawal was linked to relapse during the quit attempt and to more use one month later.

Readers curious about how cannabis withdrawal relates to daily functioning, relapse during a quit attempt, and short-term outcomes in a small, monitored sample.

2 weeks
the monitored abstinence period during which daily withdrawal-related interference was tracked

What the researchers found

People who felt that withdrawal was getting in the way of normal activities reported higher withdrawal severity, and those two measures moved together with a strong statistical signal. Participants with more severe dependence before stopping reported more disruption from withdrawal once they tried to abstain.

During the two-week abstinence window, relapse was associated with greater interference from a subset of withdrawal symptoms among those with high dependence. Looking beyond the quit attempt, higher levels of withdrawal-related functional impairment during abstinence statistically predicted higher cannabis use at the one-month follow-up. These are associations in a small, volunteer sample, not proof that withdrawal caused relapse or later use.

Why it matters

At the time, there was debate about whether cannabis withdrawal meaningfully affects daily life. This study quantified interference with normal activities and found that higher disruption tracked with relapse during abstinence and with heavier use a month later. It frames withdrawal not just as a list of symptoms, but as something that can be tied to everyday functioning and the course of a quit attempt.

The numbers in context

- Sample: 49 non-treatment seeking adults with DSM-IV cannabis dependence

- Timeline: 1-week baseline, 2 weeks of monitored abstinence, 1-month follow-up

- Withdrawal interference and symptom severity moved together (p=0.0001), indicating a strong statistical link

- Greater dependence severity at baseline tracked with more withdrawal-related interference during abstinence (p=0.03)

How the study worked

Prospective observational study. Forty-nine non-treatment seeking adults who met DSM-IV criteria for cannabis dependence completed a one-week baseline, followed by two weeks of monitored abstinence and a one-month follow-up. Each day, they rated how much withdrawal symptoms interfered with normal activities, producing a 'functional impairment' score. Analyses tested links between impairment, symptom severity, dependence severity at baseline, relapse during abstinence, and use at one month. There was no control group and impairment was self-reported.

Who was studied

N=49 non-treatment seeking cannabis users meeting DSM-IV criteria for dependence, Country not specified.

What this study cannot tell us

Small sample (49) limits precision. Non-treatment seeking volunteers may not resemble people seeking help. Relapse analyses drew on a small subgroup, raising the risk of unstable estimates. Outcomes relied on self-reported daily interference without objective verification. The study was observational with no control group, so it cannot establish causality. Product types, potencies, ages, and sex distribution were not detailed in the abstract. Country was not specified.

How to read the evidence

Rated preliminary: small prospective observational study with volunteer, non-treatment seeking participants, self-reported outcomes, and a small relapse subgroup. Associations are statistically strong in places but cannot show causality.

When this study was published

Published in 2012, just before DSM-5 formally recognized cannabis withdrawal in 2013. Product profiles and use patterns have shifted since, which could affect withdrawal experiences.

The bigger picture

Cannabis withdrawal was formally recognized in DSM-5 the year after this paper. This study helped quantify why, linking withdrawal to real-world disruption and to outcomes during and after an abstinence attempt. It also distinguishes between symptom severity and functional impact, a difference that matters for research design and interpretation. The sample was small, volunteer, and not in treatment, so whether the same patterns appear in clinical settings or with today’s product landscape remains an open question.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Which specific withdrawal symptoms most strongly track with functional impairment and relapse risk?
Would the same associations appear in treatment-seeking populations or in larger, more diverse samples?
Do objective measures of functioning or biomarkers align with self-reported interference scores?
How do product potency, frequency of use, or route of administration relate to withdrawal-linked functional impairment?

Common questions

What did 'functional impairment' mean in this study?

Participants rated how much withdrawal symptoms interfered with normal daily activities each day during abstinence. It is a self-reported measure of disruption, not an objective test.

Did withdrawal cause people to relapse?

Causality cannot be determined here. Higher withdrawal-related interference was associated with relapse during abstinence and with more use at one month, but this was an observational design.

Who were the participants?

Forty-nine adults who met DSM-IV criteria for cannabis dependence and were not seeking treatment. They completed a one-week baseline, two weeks of monitored abstinence, and a one-month follow-up.

Read the original research

Quantifying the clinical significance of cannabis withdrawal

PLOS ONE, 7(9), e44864

PLOS ONE is a peer-reviewed open access scientific journal covering primary research from any discipline within science and medicine.

View on PubMed ↗Publisher’s paper ↗

Citation

Allsop, David J.; Copeland, Jan; Norberg, Melissa M.; Fu, Shanlin; Molber, Anna; Budney, Alan J.; et al.. (2012). Quantifying the clinical significance of cannabis withdrawal. PLOS ONE, 7(9), e44864. https://doi.org/10.1371/journal.pone.0044864